Pioneering access for patients
Our Vision is to be the world’s leading and most valued generics and biosimilars company.
Download full reportHighlights
2024 by the numbers
Financial highlights1
Net sales to third parties2
Core EBITDA margin
Management Free Cash Flow
operating income
CORE DILUTED EPS
CORE ROIC
Non-financial highlights3
Patient treatments
provided
treatments provided
Savings delivered to US AND
EUROPEAN healthcare systems
our key products
Social impact
our key products annually4
- Non-IFRS measures are defined in Supplementary financial information section of the complete 2024 Integrated Annual Report.
- Net sales on this website and in our Integrated Annual Report refer systematically to net sales to third parties. In the first nine months of 2023, third-party sales excluded sales to our former parent. Post spin-off, sales to our former parent are reported as third-party sales.
- For definitions of our non-financial indicators, please see Sandoz.com/ESG_supplementary_disclosures_2024.
- Estimate from 2023. For details please see Sandoz.com/ESG_supplementary_disclosures_2024.
Letters to shareholders
Our Purpose enables us to drive performance and create value for our stakeholders.
I am honored and pleased to introduce our second Integrated Annual Report, marking our first full year as an independent public company.
We have successfully completed our first full year as an independent company, with strong sales growth, clear margin progression to fund our future operations and consistent delivery on our strategic milestones.
2024 in review
A year of consistent
delivery
first multiple sclerosis biosimilar.
(biosimilar ranibizumab) from Coherus.
WYOST® / JUBBONTI®
denosumab biosimilars.
OF PYZCHIVA®
FOR ENZEEVU®
Our strategy
Our strategy for creating shareholder and societal value
Three phases
In our second year as a standalone global leader, the Sandoz strategy remains fundamentally unchanged. We are building consistently on our solid foundations, with our strong leadership in home market Europe and strategic leadership ambitions in the key US market, to succeed in the long term. The strategy is evolving in three clear phases:
Leveraging our freedom as a
standalone company
Establishing a world-class generics and
biosimilars company
Long-term leadership
Sandoz continues to optimize its product mix, with mid-term growth driven by a combination of increased volume in the base business and launches across generics and biosimilars. Together with the benefit from strong existing infrastructure and customer relationships, this generates attractive cash flow to support future investments.
Global reach
We produce quality generic and biosimilar medicines at scale
| Europe | 0m | 0% | |
| North America | 0m | 0% | |
| International | 0m | 0% |
| Europe | USD 0.0bn | 0% | |
| North America | USD 0.0bn | 0% | |
| International | USD 0.0bn | 0% |
- Calculated based on Sandoz treatments delivered (volumes sold); defined daily dose (according to the WHO); and treatment duration, based on Sandoz medical experts’ guidance.
ESG overview
Our ESG strategy has four pillars.
Driving impact and access to healthcare is at the core of what we do. Championing sustainability, empowering our people, and governing with integrity help us to advance our Purpose and integrate it into our strategy.
Driving Impact and Access
Pioneering access to generic and biosimilar medicines worldwide is central to what we do. We produce quality medicines at scale, making them more accessible and affordable, while partnering to accelerate the pace of change.
Championing Sustainability
We prioritize environmental sustainability, driving down our carbon footprint and preserving natural resources.
Empowering our People
People are central to our Purpose of pioneering access for patients. We foster a safe and diverse workforce and develop exceptional talent and an inclusive pioneering culture.
Governing with Integrity
We promote strong corporate governance that drives sound risk management, ethical behavior, and safe high-quality products.
- Impact & Access to Healthcare
- Climate Change
- Pollution (including AMR)
- Supplier Management
- Diversity, Equity & Inclusion
- Corporate Culture
- Health & Safety
- Ethics, Corruption & Bribery
- Product Quality & Safety
- Data Privacy & Cybersecurity
Our top priority is to tackle unsustainable market conditions and practices that hinder access to vital generic medicines.“
